Rheumatology
News
Adverse event rates compared for colchicine, NSAIDs when starting allopurinol for gout
Patients receiving prophylactic colchicine or NSAIDs with initiation of allopurinol for gout have more adverse events than those who receive no...
News
More evidence shows COVID-19’s link to risk for autoimmune disease
Patients with more severe COVID-19 that required hospitalization in the ICU were more likely to develop vasculitis, alopecia totalis, and several...
News
Colchicine still needed to prevent gout flares in allopurinol ‘start-low, go-slow’ strategy
Patients taking colchicine had fewer gout flares than did those taking placebo for the first 6 months, but the number evened out between the two...
News
Diabetes drug class appears to reduce recurrent gout flares
Previously associated with a lower incidence of gout, SGLT2 inhibitors for the first time also appear to reduce gout flare recurrence and excess...
News from the FDA/CDC
FDA approves canakinumab for gout flares
Canakinumab is the first biologic in the U.S. approved for treating gout flares.
News
Study validates use of new psoriatic arthritis prediction tool
To develop the tool, researchers evaluated 635 patients with psoriasis from a prospective longitudinal cohort study evaluating risk factors for...
News
Low-dose steroids may not increase cardiovascular risk in rheumatoid arthritis
A daily prednisolone dose of less than 5 mg was not associated with increased cardiovascular risk, whereas a dose of 5 mg or more doubled the risk...
News
Could GLP-1 receptor agonists ease knee osteoarthritis pain, slow progression?
Weight loss is recommended for patients with knee osteoarthritis (KOA), and GLP-1 RAs are approved for weight loss. Early research suggests these...
News
SGLT2 inhibitors linked with fewer gout flares in diabetes
“SGLT2 inhibitors may offer distinct benefits,” making the drug class “a particularly attractive addition to current urate-lowering therapies.”
News
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
Experts in rheumatology, dermatology, and gastroenterology assess the potential of colchicine 0.5 mg to treat residual risk for atherosclerotic...